Table 2

Variables analyzed in meta-analysis

Aflatoxin exposureNo. of studiesNo. of tumorsMean proportion of tumors percentage (95% CI)a
Presence of any p53 mutation among all of the tumorsbLow1542019 (14–25)
Medium1030626 (18–34)
High711457 (46–68)
Total32840
Presence of p53 249ser mutation among all of the tumorsLow196512 (0–6)
Medium154599 (4–14)
High1325950 (42–58)
Total471369
Presence of a p53 249ser mutation among tumors with p53 mutationsLow141012 (0–10)
Medium108627 (13–40)
High76492 (80–100)
Total31251
Presence of non-249ser p53 mutations among all of the tumors without a mutation in codon 249Low1541519 (13–24)
Medium1027818 (11–25)
High7575 (0–14)
Total32750
Presence of HBV infection among all of the tumorscLow1647941 (31–51)
Medium1238978 (67–89)
High1325591 (80–100)
Total411123
Difference between the presence of any p53 mutation among HBV+ and HBV− tumorsLow13332−3 (−16–9)
Medium724018 (1–35)
High456−1 (−25–23)
Total24628
Difference between the presence of p53 249ser mutation among HBV+ and HBV− tumorsLow154243 (−6–11)
Medium93328 (−4–20)
High81538 (−9–24)
Total32909
  • a Weighted to reflect both within-study and between-study variation as well as the sample size in each study.

  • b Mutations detected by sequencing exons 4–8 of p53 gene.

  • c HBV status detected by a variety of techniques as described in “Materials and Methods.”